10:30 AM EDT, 05/03/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target price to $222 from $253, reflecting 16.2x our 2024 EPS estimate, a discount to TFX's historical forward average due to our forecasts of a slowing growth rate. We trim our 2024 EPS estimate by $0.02 to $13.73 and widen 2025's by $0.78 to $15.25. TFX reported Q1 EPS of $3.21 vs. $3.09, beating the S&P Capital IQ consensus estimte by $0.14 driven by solid performance by the Interventional and OEM business segments due to strong sales of complex catheters and intra-aortic balloon pumps. UroLift growth was negatively impacted by continued challenges in the office side of service and sales force training activities on the use of Barrigel (following the October 2023 acquisition of Palette Life Sciences). We anticipate future growth in TFX's cath lab, where procedure volumes globally are back to pre-pandemic levels, through near-term market launches, M&A, and R&D spend to develop future products.